SKYE
Skye Bioscience, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-38/100
Last price
1.65
▲ 0.03 (2.16%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.69
Prev close
1.62
Day high
1.68
Day low
1.62
Volume
11.48K
Market cap
$7.33M
P/E (TTM)
—
52W range
1.50 – 14.51
Day trading desk
Gap from prior close
+4.61%
Prior close 1.62
VWAP
1.66
-0.30% from price
Relative volume
0.13×
Quiet session
Session range
4.61%
1.62 – 1.69
Position in range
47%
Mid range
ATR (14D)
0.16
9.61% of price
Prior day high
1.77
PDH
Prior day low
1.62
PDL
Bid / ask spread
—
Quote not published
Session volume
11.56K
Avg 88.22K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+2.80%
+1.1%
1M
-11.97%
-13.3%
3M
-70.49%
-73.7%
6M
-70.74%
-85.5%
YTD
-72.42%
-86.2%
1Y
-89.11%
-104.6%
3Y
-94.74%
-176.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SKYE open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+121.85M
Net buying
Buy transactions
23
132.30M shares
Sell transactions
16
10.45M shares
Net transactions
+39
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
187.73K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 23, 26 | SCHWAB ANDREW J. Director and Beneficial Owner of more than 10% of a Class of Security |
SELL | 148.08K | $239.56K | Indirect |
| Sep 23, 26 | 5AM PARTNERS VII, LLC Beneficial Owner of more than 10% of a Class of Security |
SELL | 148.08K | $239.56K | Indirect |
| Aug 20, 26 | SCHWAB ANDREW J. Director and Beneficial Owner of more than 10% of a Class of Security |
SELL | 375.84K | $140.31K | Indirect |
| Aug 20, 26 | 5AM PARTNERS VII, LLC Beneficial Owner of more than 10% of a Class of Security |
SELL | 375.84K | $140.31K | Indirect |
| Aug 7, 26 | DHILLON PUNIT S Chief Executive Officer |
— | 1.09M | — | Direct |
| Aug 22, 25 | SCHWAB ANDREW J. Director and Beneficial Owner of more than 10% of a Class of Security |
SELL | 231.41K | $800.55K | Indirect |
| Aug 22, 25 | 5AM PARTNERS VII, LLC Beneficial Owner of more than 10% of a Class of Security |
SELL | 231.41K | $800.55K | Indirect |
| Nov 18, 24 | GRAYSON PAUL A. Director |
SELL | 86.55K | $432.06K | Direct |
| Nov 18, 24 | DHILLON PUNIT S Chief Executive Officer |
SELL | 82.91K | $413.93K | Direct |
| Nov 18, 24 | ARSENAULT KAITLYN MELANIE Chief Financial Officer |
SELL | 43.21K | $215.60K | Direct |
| Nov 18, 24 | ARSENAULT KAITLYN MELANIE Chief Financial Officer |
SELL | 43.22K | $215.75K | Direct |
| Nov 18, 24 | DIEP TUAN TU Officer |
SELL | 19.57K | $97.72K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
5AM PARTNERS VII, LLC |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
ARSENAULT KAITLYN MELANIE |
Chief Financial Officer | 166.34K | Sale |
DHILLON PUNIT S |
Chief Executive Officer | 1.43M | Stock Award(Grant) |
DIEP TUAN TU |
Officer | 82.26K | Sale |
GRAYSON PAUL A. |
Director | 259.70K | Sale |
SCHWAB ANDREW J. |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Sale |
Fundamentals
Market cap$7.33M
Enterprise value$-2.71M
Revenue (TTM)—
Gross profit—
EBITDA$-47.37M
Net income$-50.49M
EPS (TTM)$-10.16
Free cash flow$-18.71M
Total cash$10.06M
Total debt$178.75K
Book value / share$-0.11
Shares outstanding4.43M
Float2.99M
Short % of float3.70%
Dividend yield0.00%
Beta (5Y)2.86
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.22
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA0.06
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-233.87%
Return on assets-95.06%
Debt / equity—
Current ratio0.95
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $42.36M | $18.70M | $5.82M | $6.01M | +126.5% |
| Selling, general & admin | $15.80M | $17.73M | $7.85M | $6.09M | -10.9% |
| Total operating expense | $58.16M | $36.43M | $13.67M | $12.11M | +59.7% |
| Operating income | -$58.16M | -$36.43M | -$13.67M | -$12.11M | -59.7% |
| Net interest income | $1.88M | $2.28M | -$806.30K | -$766.35K | -17.4% |
| Pre-tax income | -$55.92M | -$26.56M | -$37.64M | -$19.47M | -110.6% |
| Tax provision | $5.40K | $10.07K | $3.60K | $6.74K | -46.4% |
| Net income | -$55.92M | -$26.57M | -$37.64M | -$19.48M | -110.5% |
| Net income to common | -$55.92M | -$26.57M | -$37.64M | -$19.48M | -110.5% |
| Basic EPS | -1.41 | -0.73 | -5.37 | -8.77 | -93.2% |
| Diluted EPS | -1.41 | -0.73 | -5.37 | -8.77 | -93.2% |
| EBIT | -$55.92M | -$25.59M | -$36.74M | -$18.81M | -118.5% |
| EBITDA | -$55.20M | -$25.29M | -$36.62M | -$18.70M | -118.2% |
| Basic shares | 39.66M | 36.49M | 7.01M | 2.22M | +8.7% |
| Diluted shares | 39.66M | 36.49M | 7.01M | 2.22M | +8.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.88M | $68.42M | $1.26M | $1.24M | — | -91.4% |
| Cash & short-term investments | $25.74M | $68.42M | $1.26M | $1.24M | — | -62.4% |
| Total current assets | $27.09M | $70.83M | $11.65M | $8.94M | — | -61.7% |
| Property, plant & equipment | $1.17M | $1.88M | $281.26K | $159.04K | — | -38.1% |
| Total assets | $28.31M | $72.76M | $11.94M | $9.11M | — | -61.1% |
| Total current liabilities | $8.21M | $4.34M | $13.90M | $12.12M | — | +89.1% |
| Current debt | — | — | $4.37M | $1.90M | $1.97M | — |
| Total debt | $273.65K | $455.59K | $4.62M | $1.98M | — | -39.9% |
| Total liabilities | $8.29M | $4.61M | $14.07M | $12.12M | — | +79.7% |
| Retained earnings | -$186.87M | -$130.95M | -$104.38M | -$66.74M | — | -42.7% |
| Shareholder equity | $20.02M | $68.15M | -$2.13M | -$3.01M | — | -70.6% |
| Working capital | $18.89M | $66.49M | -$2.25M | -$3.18M | — | -71.6% |
| Net tangible assets | $20.02M | $68.15M | -$2.13M | -$3.01M | — | -70.6% |
| Shares issued | 33.38M | 30.97M | 12.35M | 3.65M | — | +7.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$55.92M | -$26.57M | -$37.64M | -$19.48M | -110.5% |
| Depreciation & amortisation | $723.35K | $298.64K | $124.25K | $115.00K | +142.2% |
| Stock-based compensation | $7.77M | $8.32M | $987.51K | $629.03K | -6.6% |
| Change in working capital | $4.73M | -$2.63M | -$469.31K | -$761.90K | +280.0% |
| Operating cash flow | -$43.06M | -$25.24M | -$13.95M | -$12.74M | -70.6% |
| Capital expenditure | -$6.31K | -$1.60M | -$12.55K | -$28.06K | +99.6% |
| Investing cash flow | -$19.50M | -$245.62K | $6.60M | $5.21M | -7,839.4% |
| Financing cash flow | $29.57K | $83.56M | $16.44M | -$208.79K | -100.0% |
| Free cash flow | -$43.07M | -$26.84M | -$13.96M | -$12.77M | -60.5% |
| End cash position | $5.88M | $68.42M | $10.34M | $1.25M | -91.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $3.94M | $7.94M | $11.47M | $9.36M | $14.34M | -50.3% |
| Selling, general & admin | $3.87M | $4.74M | $3.43M | $3.91M | $3.91M | -18.3% |
| Total operating expense | $7.81M | $12.67M | $14.90M | $13.26M | $18.24M | -38.4% |
| Operating income | -$7.81M | -$12.67M | -$14.90M | -$13.26M | -$18.24M | +38.4% |
| Net interest income | $99.91K | $167.42K | $274.10K | $418.47K | $533.09K | -40.3% |
| Pre-tax income | -$10.78M | -$12.51M | -$14.44M | -$12.75M | -$17.62M | +13.8% |
| Tax provision | $3.40K | $0 | $0 | $0 | $3.40K | — |
| Net income | -$10.79M | -$12.51M | -$14.44M | -$12.75M | -$17.62M | +13.8% |
| Net income to common | -$10.79M | -$12.51M | -$14.44M | -$12.75M | -$17.62M | +13.8% |
| Basic EPS | -0.27 | -0.32 | -0.36 | -0.32 | -0.44 | +15.6% |
| Diluted EPS | -0.27 | -0.32 | -0.36 | -0.32 | -0.44 | +15.6% |
| EBIT | -$10.78M | -$12.51M | -$14.44M | -$12.75M | -$17.62M | +13.8% |
| EBITDA | -$10.62M | -$12.33M | -$14.26M | -$12.58M | -$17.43M | +13.9% |
| Basic shares | 39.69M | 39.68M | 39.67M | 39.67M | 39.66M | +0.0% |
| Diluted shares | 39.69M | 39.68M | 39.67M | 39.67M | 39.66M | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.07M | $8.15M | $5.88M | $18.44M | $23.84M | -1.0% |
| Cash & short-term investments | $10.06M | $17.11M | $25.74M | $35.31M | $48.59M | -41.2% |
| Total current assets | $10.96M | $18.57M | $27.09M | $39.92M | $50.58M | -41.0% |
| Property, plant & equipment | $66.60K | $813.86K | $1.17M | $1.35M | $1.52M | -91.8% |
| Total assets | $11.03M | $19.42M | $28.31M | $41.32M | $52.16M | -43.2% |
| Total current liabilities | $11.53M | $10.40M | $8.21M | $8.37M | $8.31M | +10.8% |
| Current debt | $143.05K | $250.34K | — | — | — | -42.9% |
| Total debt | $178.75K | $311.32K | $273.65K | $321.85K | $367.54K | -42.6% |
| Total liabilities | $11.53M | $10.40M | $8.29M | $8.49M | $8.48M | +10.8% |
| Retained earnings | -$210.17M | -$199.38M | -$186.87M | -$172.43M | -$159.68M | -5.4% |
| Shareholder equity | -$497.31K | $9.01M | $20.02M | $32.84M | $43.68M | -105.5% |
| Working capital | -$572.22K | $8.16M | $18.89M | $31.56M | $42.27M | -107.0% |
| Net tangible assets | -$497.31K | $9.01M | $20.02M | $32.84M | $43.68M | -105.5% |
| Shares issued | 35.14M | 35.13M | 33.38M | 30.99M | 30.99M | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$10.79M | -$12.51M | -$14.44M | -$12.75M | -$17.62M | — | +13.8% |
| Depreciation & amortisation | $157.60K | $172.89K | $180.01K | $178.90K | $187.07K | — | -8.8% |
| Stock-based compensation | $1.27M | $1.50M | $1.62M | $1.91M | $2.03M | — | -15.1% |
| Change in working capital | -$1.43M | $2.27M | $3.06M | -$2.61M | $4.75M | — | -162.7% |
| Operating cash flow | -$7.12M | -$8.56M | -$9.77M | -$13.36M | -$10.75M | — | +16.8% |
| Capital expenditure | — | — | — | — | — | -$6.31K | — |
| Investing cash flow | $7.14M | $10.90M | -$2.80M | $7.97M | -$11.86M | — | -34.5% |
| Financing cash flow | -$101.01K | -$71.53K | $11.41K | $0 | $18.16K | — | -41.2% |
| Free cash flow | -$7.12M | -$8.56M | -$9.77M | -$13.36M | -$10.75M | — | +16.8% |
| End cash position | $8.07M | $8.15M | $5.88M | $18.44M | $23.84M | — | -1.0% |
Options analytics
Put / call volume
0.30
Call-heavy session
Put / call open interest
0.04
Positioning, not flow
Max pain
2.50
+51.1% from spot
ATM implied vol
68.8%
Nearest strike to spot
Skew (10% OTM)
+578.1%
Puts bid over calls
Call volume
27
Contracts, this expiry
Put volume
8
Contracts, this expiry
Heaviest call OI
2.50
3.12K contracts
Heaviest put OI
2.50
118 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -2.11 | -1.55 | +26.2% |
| Mar 2026 | -2.59 | -2.56 | +1.0% |
| Dec 2025 | -2.45 | -2.95 | -20.2% |
| Sep 2025 | -2.56 | -2.59 | -1.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.12 | 1 | $0 | 0.0% |
| Next quarter | -1.12 | 1 | $0 | 0.0% |
| Current year | -5.04 | 1 | $0 | 0.0% |
| Next year | -7.40 | 4 | $0 | 0.0% |
Analyst targets & ownership
Mean target$68.00
High target$160.00
Low target$16.00
Implied upside4008.76%
Analyst count4
ConsensusNONE
Strong buy / Buy0 / 2
Hold2
Sell / Strong sell0 / 0
Held by insiders4.24%
Held by institutions40.17%
Institutions holding36
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.65
+0.52% from price
SMA 20
1.75
-5.46% from price
SMA 50
2.57
-35.49% from price
SMA 100
4.15
-60.08% from price
SMA 200
5.34
-69.04% from price
EMA 12
1.69
-2.02% from price
EMA 26
1.93
-14.27% from price
EMA 50
2.58
-35.74% from price
RSI (14)
37.7
Neutral
MACD (12,26,9)
-0.24
Hist 0.07
ATR (14)
0.16
9.61% of price
Realised vol 30D
109.6%
Annualised
Bollinger upper
2.08
20, 2σ
Bollinger lower
1.42
20, 2σ
50 / 200 cross
Death
2.57 vs 5.34
Trend bias
Below 200
-69.04%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.93
Less volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
109.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-88.7%
Peak to trough
Max drawdown 5Y
-99.1%
Peak to trough
ATR 14
0.16
9.61% of price
Beta (reported)
2.86
5Y monthly, from filing
Short interest
Shares short
117.09K
Prior 150.45K
Change vs prior
-22.2%
Shorts covering
% of float
3.70%
Normal
% of shares out
2.64%
Against total outstanding
Days to cover
0.7
Liquid
Float
2.99M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 25 | HC Wainwright & Co. | INITIATED | — | Buy |
| Aug 15, 25 | Evercore ISI Group | INITIATED | — | Outperform |
| Jun 24, 25 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| Mar 21, 25 | Craig-Hallum | MAINTAINED | Buy | Buy |
| Mar 21, 25 | Citizens Capital Markets | MAINTAINED | Market Outperform | Market Outperform |
| Feb 28, 25 | William Blair | INITIATED | — | Outperform |
| Sep 30, 24 | Scotiabank | INITIATED | — | Sector Outperform |
| Sep 20, 24 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Sep 20, 24 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Sep 10, 24 | JMP Securities | INITIATED | — | Market Outperform |
| Sep 9, 24 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Sep 6, 24 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:8
Split dateAug 24, 2026
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-11
Proxy Statements
DEFA14A · 2026-08-24
Proxy Statements
DEFA14A · 2026-08-20
Proxy Statements
DEFA14A · 2026-08-19
Periodic Financial Reports
10-Q · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-06-23
Corporate Changes & Voting Matters
8-K · 2026-05-29
Corporate Changes & Voting Matters
8-K · 2026-05-15
Headlines
Skye Bioscience Inc (SKYE) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Fibrex ...
GuruFocus.com · 51d ago
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
GlobeNewswire · 54d ago
The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea
Yahoo Finance · 82d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.